Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to look for.
Collegium Pharmaceutical beat analysts’ revenue expectations last quarter, reporting revenues of $193.5 million, up 8.9% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance missing analysts’ expectations significantly.
Is Collegium Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Collegium Pharmaceutical’s revenue to grow 7% year on year, slowing from the 29.4% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Collegium Pharmaceutical rarely misses Wall Street’s revenue estimates.
Looking at Collegium Pharmaceutical’s peers in the branded pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb delivered year-on-year revenue growth of 5.7%, beating analysts’ expectations by 12.9%, and Corcept reported revenues up 7.3%, falling short of estimates by 1%. Bristol-Myers Squibb traded up 3.5% following the results while Corcept was also up 27.3%.
Read our full analysis of Bristol-Myers Squibb’s results here and Corcept’s results here.
Investors in the branded pharmaceuticals segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Collegium Pharmaceutical is down 4.7% during the same time and is heading into earnings with an average analyst price target of $53.60 (compared to the current share price of $35.72).
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
